BCLI has completed a phase 3 trial in ALS. Despite not meeting the primary endpoint BCLI is still applying for approval and an AdCom meeting is scheduled for September 27. NurOwn was significantly ...
NEW YORK, Oct. 28, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of ...
TEL AVIV (Reuters) - Data from the first ALS patients in a clinical trial treated with BrainStorm Cell Therapeutics adult stem cell therapy did not show significant side effects and the treatment has ...
July 7 - BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, has completed a preclinical study in collaboration with the W.M. Keck ...
Food and Drug Administration scientists have “major concerns” with an application filed by biotechnology company BrainStorm Cell Therapeutics for approval of a personalized stem cell treatment for ...
The human mind is a complex system with billions of neurons that allow it to perform many functions, one of which is to think and generate ideas. Experts estimate that the mind thinks between 60,000 ...
Within creative problem-solving, brainstorming stands as a fundamental technique. Traditionally, brainstorming involves a group of individuals generating ideas to address a specific problem. However, ...
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. BrainStorm holds the rights to clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results